BACKGROUND: The main goal is to analyze the evolution of the consumption of @entity2124 (Somatropin) at the Valencia region (Spain). The research focuses on the period comprising 2003-2007 and aims at assessing the impact of the change in the conditions of dispensation of the hormone (May 2005) as well as of the approval of a new indication in 2004. We have also studied the number of treated @entity1 and expenses saved in public money due to the denial of certain treatments. METHODS: The @entity1 data have been obtained from a proprietary database owned by the regions government, this database contains information about the requests for treatment and the consumption of @entity2124 has been obtained from database Gaia and drug consumption in the hospital. The data are expressed in terms of number of treated @entity1 , consumed milligrams and cost. RESULTS: The number of @entity1 treated with @entity2124 has increased 50% (from 346 @entity1 in 2003 to 520 in 2007). The denial of requests for treatment has made it possible to save 3.912.253 capital JE, Ukrainian. The cost per mg of @entity2124 has decreased from 27.35 capital JE, Ukrainian in 2003, when the hormone was dispensed in local pharmacy stores, to 22.34 capital JE, Ukrainian in 2007, when it was dispensed at hospitals pharmacies. The change in the conditions in which the drug is dispensed has led to a reduction of 18.3% considering current costs. CONCLUSIONS: The number of treated @entity1 has increased a 50% from 2003 to 2007. In this period of time has been approved a new indication. The cost/mg has been reduced a 18,3 % due to the change in the conditions of dispensation. The Advisory Committee has contributed to the utilization of @entity2124 according to rational drug use criteria.

[Utilization of XXXX in Valencia Region, Spain, during the period 2003-2007].

@entity2124 :: ('2688', 'Gene') :: ['growth hormone'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient']
@entity2124 :: (2688,Gene) :: ['growth hormone']
